GlobeNewswire by notified

Evs Invites Its Shareholders to the Ordinary General Meeting and an Extraordinary General Meeting on May 21, 2024

Share

Publication on April 19, 2024, at 6:30 am before market opening
Regulated information
EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR)

EVS INVITES ITS SHAREHOLDERS TO THE ORDINARY GENERAL MEETING AND AN EXTRAORDINARY GENERAL MEETING ON MAY 21, 2024

EVS Broadcast Equipment, leading provider of live video production systems, published today the invitation to its Ordinary General Meeting, to be held on May 21, 2024, at 11 am, at its registered office in Liège, to deliberate on the agenda available on the website of the company (see link below).

Aside from the usual topics, including the 2023 annual and sustainability reports, the Board of Directors will propose to the Shareholders to approve the following resolutions:

  • The payment of a total gross dividend of EUR 1.10 per share (including the interim dividend of EUR 0.50 paid in November 2023);
  • A profit-sharing plan in the form of a grant of 36 EVS shares for each EVS employee, in proportion to their effective services in 2023;
  • Board mandates:
    • The renewal of the mandate of The House of Value – Advisory & Solutions BV, represented by Mr. Johan Deschuyffeleer, as independent Director;
    • The renewal of the mandate of Innoconsult BV, represented by Mr. Martin De Prycker, as independent Director;

                        and

  • The renewal of the mandate of Mr. Michel Counson as Director.

An Extraordinary General Meeting of the company will also be held on the same day, at 12 am, at its registered office in Liège, to deliberate on the agenda available on the website of the company (see link below). The Board of Directors will propose to this effect to the Shareholders to approve the issuance of subscription rights (warrants).

The convocation and all documents relating to the General Meetings of May 21, 2024 are available on the website of EVS Broadcast Equipment at https://evs.com/en/corporate/corporate-governance/general-meetings, including the 2023 annual and sustainability reports.

For more information, please contact:



Veerle De Wit, CFO*
EVS Broadcast Equipment S.A., Liege Science Park, 13 rue Bois Saint-Jean, B-4102 Seraing, Belgium
Tel: +32 4 361 70 04.  E-Mail:corpcom@evs.com; www.evs.com
* representing a SRL


Forward Looking Statements
This press release contains forward-looking statements with respect to the business, financial condition, and results of operations of EVS and its affiliates. These statements are based on the current expectations or beliefs of EVS's management and are subject to a number of risks and uncertainties that could cause actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. These risks and uncertainties relate to changes in technology and market requirements, the company’s concentration on one industry, decline in demand for the company’s products and those of its affiliates, inability to timely develop and introduce new technologies, products and applications, and loss of market share and pressure on pricing resulting from competition which could cause the actual results or performance of the company to differ materially from those contemplated in such forward-looking statements. EVS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

About us
We create return on emotion



EVS is globally recognized as leading provider in live video technology for broadcast and new media productions. Spanning the entire production process, EVS solutions are trusted by production teams worldwide to deliver the most gripping live sports images, buzzing entertainment shows and breaking news to billions of viewers every day – and in real-time. As we continue to expand our footprint, our dedication to sustainable growth for both our business and the industry is clearly demonstrated through our ESG strategy. This commitment is not only reflected in our results, but also in our high ratings from different agencies.
Headquartered in Liège, Belgium, the company has a global presence with offices in Australia, Asia, the Middle East, Europe, North and Latin America, employing over 600 team members and ensuring sales, training and technical support to more than 100 countries.
EVS is a public company traded on Euronext Brussels: EVS, ISIN: BE0003820371.
For more information, please visit www.evs.com.




Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 20242.5.2024 07:30:49 CEST | Press release

Bagsværd, Denmark, 2 May 2024 - financial report for the period 1 January 2024 to 31 March 2024 Operating profit increased by 27% in Danish kroner and by 30% at constant exchange rates (CER) to DKK 31.8 billion. Sales in North America Operations increased by 34% in Danish kroner (35% at CER). Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years. Sales in International Operations increased by 8% in Danish kroner (11% at CER).Sales within Diabetes and Obesity care increased by 25% in Danish kroner to DKK 61.0 billion (27% at CER), mainly driven by GLP-1 diabetes sales growth of 30% in Danish kroner (32% at CER) and Obesity care growing by 41% in Danish kroner to DKK 11.0 billion (42% at CER). Rare disease sales decreased by 4% measured in Danish kroner (3% at CER).In the first quarter of 2024, Novo Nordisk successfully completed the FLOW kidney outcomes trial with semaglutide 1.0 mg. Further, Wegovy® was approved in the US for cardiovasc

Promising start to the year with continued business improvements2.5.2024 07:30:28 CEST | Press release

Company Announcement Copenhagen, 2 May 2024 No. 19/2024 Trading update for 1 January – 31 March 2024 Promising start to the year with continued business improvements Highlights Organic growth was 6.0% in Q1 2024 (Q1 2023: 12.0%). Total revenue for the quarter amounted to DKK 20.1 billion (Q1 2023: DKK 19.3 billion).The organic growth development was mainly driven by successful implementation of price increases to offset wage increases and general cost inflation and volume growth.The operating margin developed in line with plan. This was mainly driven by continued operational improvements and efficiencies. Costs related to mobilisation of contracts won in 2023 have been incurred in the quarter. During the first months of the year, ISS has secured several smaller and mid-sized local IFS contract wins and extended contracts with Nordea and a global bank.In the beginning of April 2024, the divestment of ISS France was completed. Financial leverage remains broadly unchanged following the di

Ipsen appoints Keira Driansky as EVP, President of North America2.5.2024 07:30:00 CEST | Press release

PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executive Leadership Team (ELT) and report directly to Ipsen’s Chief Executive Officer (CEO), David Loew. “We are thrilled to welcome Keira to Ipsen as our new President of North America as she brings extensive experience in the life sciences industry and a proven track record of leadership to our team,” said David Loew, CEO Ipsen. “As we continue to navigate the complexities of the pharmaceutical landscape, Keira’s strategic vision will be instrumental in guiding our company toward a future of bringing groundbreaking medicines and enhanced outcomes to patients.” Keira will be joining Ipsen from AstraZeneca, where she spent the last 13 years leading teams across the US, Europe and global functions. Most recently Keira served as Country Presid

Intervest Offices & Warehouses NV: Press release – Persbericht – Communiqué de presse: results of Simplified Squeeze-Out Acceptance Period of TPG on Intervest2.5.2024 07:30:00 CEST | Press release

Dear Madam, Sir, Please find hereunder the links to Intervest Offices & Warehouses’ latest press release regarding the results of Simplified Squeeze-Out Acceptance Period of TPG on Intervest. Geachte mevrouw, meneer, Gelieve hierbij de links te vinden naar het recente persbericht van Intervest Offices & Warehouses betreffende de resultaten aan van de Aanvaardingsperiode van het vereenvoudigd uitkoopbod van TPG op Intervest. Chère Madame, Cher Monsieur, Veuillez trouver ci-dessous les liens vers le récent communiqué de presse d’Intervest Offices & Warehouses concernant les résultats de la période d'acceptation de l’offre de reprise simplifiée de TPG sur Intervest. Attachments EN_Intervest results squeezeout_finNL_Intervest results squeezeout_finFR_Intervest results squeezeout_fin

Pandora delivers 18% organic growth in Q1 – raises 2024 revenue guidance2.5.2024 07:30:00 CEST | Press release

Financial highlights The second phase of Pandora’s Phoenix strategy is off to a strong start. Increased investments are elevating brand desirability and showcasing Pandora’s position as a full jewellery brand.Continued momentum, helped by the early restaging of the brand, drives strong Q1 2024 trading; organic growth ends at 18% with Like-for-like (LFL) growth of 11% and network expansion of 5%.In absolute terms, revenue increased by DKK 1.0 billion compared to Q1 2023.LFL growth in key European markets of 9%, US remaining solid at 9% and Rest of Pandora at 18%.The gross margin reached a new record-high of 79.4%, +190bp vs Q1 2023, supported by channel mix, pricing and efficiencies, as well as some tailwind from silver prices and foreign exchange rates.The Q1 2024 EBIT margin landed at 22.0%, +50bp ahead of last year, reflecting the strong growth which more than offset the planned step-up in marketing investments as part of the restaging of the brand. Leverage remains low at a NIBD/EBI

HiddenA line styled icon from Orion Icon Library.Eye